BioSpace News Archive

With a rising trend in the consumerism of healthcare, as well as a broad public adoption of smart devices and IoT connected technologies, premier healthcare providers are entrusting SONIFI Health to bring more personalized hospital experiences and improved operational efficiencies to their facilities.

StimGuard prepares for market readiness for the world’s first office based drug free OAB Stimulator System for urology indications

Health Canada continues to affirm that vaping is a less harmful choice than smoking and this message needs to be reflected on new warning labels for vape products – Rothmans, Benson & Hedges Inc. recommended in a submission to Health Canada on proposed new vaping regulations for advertising, promotion and labelling.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its BRACAnalysis® CDx test as a companion diagnostic to AstraZeneca’s (LSE/OMX Nordic/NYSE: AZN) and Merck’s PARP inhibitor Lynparza® (olaparib) for men with metastatic castration-resistant prostate cancer.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced it has entered into a co-promotion agreement with Xellia Pharmaceuticals for the promotion of Biorphen® (phenylephrine HCl), the first and only FDA approved ready-to-use formulation of phenylephrine injection indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

For investors seeking outsized growth, Life Sciences--the more speculative end of the healthcare sector--is certainly one sub-industry that’s hard to beat. Granted, investments in this space might carry a greater degree of risk, but that can be said of almost any prospect in an emerging high-growth industry

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the pivotal Phase 3 trial evaluating its anti-PD-1 antibody tislelizumab in combination with two chemotherapy regimens for the first-line treatment of patients with squamous non-small cell lung cancer (NSCLC),

ANSYS Academic Program empowers tomorrow’s engineers to make an immediate impact in the workforce [21-January-2020] PITTSBURGH , Jan. 21, 2020 /PRNewswire/ -- ANSYS (NASDAQ: ANSS) is paving the way for the next generation of innovation by lowering the barrier of adoption for simulation software through its growing academic program. Free student software — a key comp

Organovo, pointing to hurdles and timeline changes in the development of its human liver tissue for transplant, announced in August 2019 that it would seek strategic alternatives.

Tauriga Sciences, Inc. announced that it is participating, this week, as a main floor Exhibitor at the prestigious Tradeshow – PGA Merchandise Show 2020.